Why BENLYSTA?

Dr. Don Thomas, Rheumatologist

Paid consultant to GSK at the time of filming.

video transcript

DR. THOMAS: My name is Doctor Don Thomas, I’ve been a rheumatologist for over 25 years, and I’m in private practice in Greenbelt, Maryland.

ON-SCREEN TEXT: Dr. Don Thomas, Rheumatologist
Paid consultant to GSK at the time of filming.

ON-SCREEN TEXT: “Why BENLYSTA?”
Stay tuned for Important Product Information

DR. THOMAS:  When you take care of a systemic lupus patient, your goal is to always try to get that patient into remission as fast as you can. And by remission what I mean is...

ON-SCREEN TEXT: “Get that patient into remission as fast as you can”

DR. THOMAS:  ... I don’t like to see any active inflammation in their history, on my physical examination, nor in the laboratory tests that I do. So, if I put someone on a medication such as an antimalarial and if they’re not in remission within a few months, then I do consider BENLYSTA as one of my therapies.

DR. THOMAS:  Number one, it’s one of the few FDA approved medications to treat systemic lupus. Number two, look at all the clinical trials that it’s passed and shown safety and efficacy. Number three, I really like the long-term extension trial which showed real world data showing a reduction in organ damage progression in patients, which I really like as well.

ON-SCREEN TEXT:

  • FDA approved
  • Clinical trial efficacy and safety
  • Long-term extension trial

DR. THOMAS: And then in addition, you don’t have to check additional labs above and beyond what you would typically need to check for with systemic lupus patients.

DR. THOMAS: So, I think BENLYSTA is an important part of our armamentarium and medications in treating systemic lupus.

ON-SCREEN TEXT: “BENLYSTA is an important part of our armamentarium”

DR. THOMAS: Thank you for watching, and visit the BENLYSTA website for more information.

ON-SCREEN TEXT: BENLYSTAHCP.com

VOICEOVER:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active central nervous system lupus. Reported: serious & sometimes fatal infections; progressive multifocal leukoencephalopathy; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

ON-SCREEN TEXT:

IMPORTANT PRODUCT INFORMATION

For patients on standard therapy: Aged 5+ and older with active SLE or active lupus nephritis. Not for use in severe active CNS lupus. Reported: serious & sometimes fatal infections; PML; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

ON-SCREEN TEXT:
BENLYSTA
(belimumab)
Intravenous Use 120 mg/vial
Subcutaneous Use 200 mg/mL

GSK Logo

Trademarks are owned by or licensed to the GSK group of companies.
©2022 GSK or licensor. BELVID220044 August 2022. Produced in USA.

You may also like

BENLYSTA patient story

Dr. Don Thomas, Rheumatologist

Why BENLYSTA?

Dr. Elaine Lambert, Rheumatologist

Paid consultants to GSK at the time of filming.

Icon: Computer

Join us for a live webinar

Learn more